文献速递消化系统肿瘤

贝伐珠单抗联合奥沙利铂、氟尿嘧啶和亚叶酸钙(FOLFOX4)用于既往治疗过的转移性结直肠癌:美国东部肿瘤协作组E3200研究结果

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200.
PubMed 文献 · J Clin Oncol · 2023-01-01

本研究为随机对照研究,829例既往接受过氟尿嘧啶和伊立替康治疗的转移性结直肠癌患者随机分为三组:FOLFOX4联合贝伐珠单抗组、FOLFOX4单用组或贝伐珠单抗单用组。主要终点总生存期在联合组为12.9个月,优于FOLFOX4单用组的10.8个月(死亡风险比=0.75;P=0.0011)和贝伐珠单抗单用组的10.2个月。结论认为在FOLFOX4基础上加用贝伐珠单抗可改善既往治疗过的转移性结直肠癌患者的生存期。

要点

  • FOLFOX4联合贝伐珠单抗组中位总生存期为12.9个月,FOLFOX4单用组为10.8个月,贝伐珠单抗单用组为10.2个月。
  • FOLFOX4联合贝伐珠单抗组中位无进展生存期为7.3个月,FOLFOX4单用组为4.7个月,贝伐珠单抗单用组为2.7个月。
  • 总缓解率分别为22.7%、8.6%和3.3%(FOLFOX4联合贝伐珠单抗组 vs FOLFOX4单用组,P<0.0001)。

核心结论

  • 在奥沙利铂、氟尿嘧啶和亚叶酸钙(FOLFOX4)基础上加用贝伐珠单抗可改善既往治疗过的转移性结直肠癌患者的生存期。

研究设计与样本

  • 美国东部肿瘤协作组E3200研究为随机对照研究,纳入829例既往接受过氟尿嘧啶和伊立替康治疗的转移性结直肠癌患者。
  • 患者随机分配至三组:FOLFOX4联合贝伐珠单抗组、FOLFOX4单用组或贝伐珠单抗单用组。
  • 主要终点为总生存期,同时评估无进展生存期、缓解率和毒性。

主要发现

  • FOLFOX4联合贝伐珠单抗组中位总生存期为12.9个月,FOLFOX4单用组为10.8个月(死亡风险比=0.75;P=0.0011),贝伐珠单抗单用组为10.2个月。
  • FOLFOX4联合贝伐珠单抗组中位无进展生存期为7.3个月,FOLFOX4单用组为4.7个月(进展风险比=0.61;P<0.0001),贝伐珠单抗单用组为2.7个月。
  • 总缓解率分别为22.7%、8.6%和3.3%(FOLFOX4联合贝伐珠单抗组 vs FOLFOX4单用组,P<0.0001)。
  • 贝伐珠单抗相关不良事件包括高血压、出血和呕吐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. PATIENTS AND METHODS: Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. RESULTS: The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. CONCLUSION: The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2023. PMID: 37459754. doi:10.1200/JCO.22.02761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。